We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,800
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Towards the Cure of CML by the Molecular Approach Strategy

Michele Cea¹², Antonia Cagnetta¹², Marco Gobbi² and Franco Patrone²
¹Dana Farber Cancer Institute, Harvard Medical School, Boston, MA;
²Department of Internal Medicine, University of Genoa, Genoa, ¹USA, ²Italy

1. Introduction

Chronic myeloid leukaemia (CML) is a hematopoietic stem cell (HSC) disorder accounting for about 15-20% of all leukemias of the adult (Goldman & Melo, 2003; Black et al., 1997). The main haematological features are represented by an increase in the number of circulating mature granulocytes and their precursors and, subsequently, by a secondary evolution in acute leukaemia.

In 1960, a major clue to the cause of CML was provided by Nowell and Hungerford who for the first time described an unusual small chromosome present in leukocytes from patients with this hematologic malignance (Nowell & Hungerford, 1960). This “minute chromosome” abnormality, designed as the Philadelphia (Ph) chromosome, after the city in which it was discovered, was found in all malignant cells of CML patients and is now considered the hallmark of this neoplasia (Nowell & Hungerford, 1960). Importantly this discovery was the first demonstration of a chromosomal rearrangement linked to a specific cancer, and had sparked searches for associations of additional chromosomal aberrations with specific forms of cancer. In 1973, Rowley demonstrated that the Ph chromosome resulted from a reciprocal translocation between the long arms of chromosomes 9 and 22, t(9:22)(q34;q11) (Rowley, 1973). Later it was shown that this process fuses the c-ABL (human homologue of the Abelson Murine Leukaemia virus), a tyrosine kinase encoding oncogene on chromosome 9, and BCR (Breakpoint Cluster Region), on chromosome 22, the function of which is still not clear (Groffen et al., 1984). This balanced translocation leads to a fusion gene, the product of which is a chimeric BCR-ABL protein equipped with cellular transforming ability which is ascribed to the elevated tyrosine kinase (TK) activity of the molecule compared to the native c-ABL (Konopka et al., 1984; Daley et al., 1990).

The biochemical signal transduction pathways stimulated by BCR-ABL kinase activity are responsible for Ph+ CML oncogenesis (Ren, 2005; Calabretta & Perrotti, 2004; Krebs & Hilton, 2001; Neshat et al., 2000; Sattler et al., 2002; Sattler et al., 1999). Further studies have established BCR-ABL as a leukaemogenic oncogene since both mouse models and in vitro assays have shown that BCR-ABL, is able to induce leukaemia (Daley & Baltimore, 1988).
2. Molecular mechanisms of BCR-ABL

Several BCR-ABL isoforms with different molecular weights have been reported (Melo & Deininger, 2004). Accordingly, while in all chimeric proteins the breakpoint within ABL gene is consistently located upstream of exon 2 (a2), the breakpoint in the BCR gene varies in its localization (Melo, 1996). A major breakpoint cluster region (M-bcr) and a minor breakpoint cluster region (m-bcr) have been defined (Kurzrock et al., 1988). The M-bcr maps to a 5.8 Kilobase (Kb) area spanning exons 12 through 16. The resulting fusion transcripts with ABL generate a 210-kDa protein named p210 which is the most common BCR-ABL form, being observed in 99% of the CML patients and in one-third of Ph-positive B cell acute lymphoblastic leukaemia (Ph+ B-ALL) (Faderl et al., 1999). m-bcr localizes to a 54.4-kb area sited downstream of exon 1. It gives rise to a fusion transcript with ABL named p190. It is rarely observed in CML, but is the most frequent BCR-ABL isoform in Ph+ B-ALL. Finally, 3’ breakpoints downstream of BCR exon 19 have also been described and they give rise to a 230-kDa fusion protein (p230 BCR-ABL), which is typically found in the rare chronic neutrophilic leukaemia (CNL) (Pane et al., 1996).

All three BCR-ABL fusion protein variants induce a similar CML-like syndrome in mice, but differ in their ability to induce lymphoid leukaemia (Li et al., 1999).

3. Cellular pathways involved in oncogenic BCR-ABL signalling

The oncogenic potential of BCR-ABL derives from its capacity to activate intracellular signalling cascades that lead to uncontrolled cell proliferation, altered cell adhesion, and apoptosis inhibition (Daley et al., 1990; Kelliher et al., 1990). To date several signalling pathways affected by the constitutively active BCR-ABL have been identified, as well as numerous binding partners and substrates that provide a link between this pathways and the defects that characterize CML. Increased susceptibility to proliferate derives from BCR-ABL’s capacity to activate the RAS-mitogen activated protein (MAP) kinase signalling cascade and JAK/STAT signalling; the interaction with SRC is responsible for increased cell motility; resistance to apoptosis is thought to result from BCR-ABL-mediated activation of phosphatidylinositol- 3-phosphate kinase (PI3K) and thereby of AKT. In summary, the net effects of these molecular alterations include inhibition of apoptosis, increased cell proliferation, aberrant interaction with the bone marrow stroma and genetic instability. Importantly all these events drive disease progression (Deninger et al., 2000).

Consistent with these molecular sequelae, BCR-ABL was shown to transform hematopoietic progenitor cells in vitro and in vivo studies (Kantarjian et al., 2006; Heilman et al., 2007). Recent reports identified a role for other signalling cascades in CML biology, including Hedgehog, Wnt and Ikaros, suggesting that pharmacological inhibitors of these pathways may find application in the treatment of CML (Chen Zhao et al., 2009; Dierks et al., 2008; Mullighan & Dowing, 2008; Dierks et al., 2008). Finally, also micro RNA (miRNA) regulation appears to apply to CML biology since miR-203, which would normally suppress BCR-ABL expression, is either mutated or epigenetically silenced in CML. In the latter type of condition, demethylating drugs such as 5-azacytidine and 4-phenylbutyrate were shown to restore miR-203 and to thereby decrease BCR-ABL expression and proliferation rate of Ph+ human CML cell lines (Faber et al., 2008; Croce & Calin, 2005).
Increasing evidence suggests that only a rare subset of immature cells within the tumor, named "leukaemia stem cells" (LSC), are able to propagate the CML (Reya et al, 2001). This cell has many common features with the hematopoietic stem cells - such as self-renewal and pluripotency pensions- unlike these, however, are refractory to conventional chemotherapy. Despite the remarkable improvements in the treatment of CML, the TKIs treatment is not curative, suppresses the disease but is not able to eradicate the CML Achilles heel, the leukaemia stem cell, causing recurrence of disease (Graham et al., 2002; Copland et al., 2006). The relapses in CML are thought to result from the outgrowth of quiescent LSC therapy-resistant, as the majority of leukemic cells in relapses represent (sub-) clones already present at diagnosis. To date the only long-term, sustainable remission derives from allogeneic bone marrow/peripheral blood stem cell transplantation which successfully restores normal hematopoiesis (Michor et al., 2005; Ljungman et al., 2009).

Recent data suggest that aberrant self-renewal is one of the central mechanisms underlying the pathogenesis of chronic myeloid leukaemia - acting either at the level of the BCR-ABL positive pluripotential stem cell in chronic phase or at the level of a more differentiated progenitor to cause blastic transformation, or most probably at both levels. Excessive self-renewal of LSCs may be mediated via several developmental pathways, including the Wnt/Frizzled/beta-catenin and Musashi-Numb pathway, or TWIST-1 oncogene and Polycomb-group protein BMI-1 (Hu et al., 2009; Ito et al., 2010; Cosset et al., 2011). An additional candidate is the Smoothened (SMO)/Sonic Hedgehog (sHH) signalling pathway, which is reasonably well characterised in solid tumours but is less well studied in leukaemia (Dierks et al., 2008; Chen Zhao et al., 2009). Particularly it is essential during embryonic development, and might play a key role in human malignancies when aberrantly activated.

4. The CML leukaemia stem cell
5. CML treatment options

The definition of the molecular structure of BCR-ABL tyrosine kinase domain has led to development of potent and specific tyrosine kinase inhibitor (TKIs) (Druker, 2008; Johnson et al., 2003). TKIs such as imatinib mesylate (Gleevec™, Novartis), nilotinib (Tasigna™, Novartis) and dasatinib (Sprycel™, Bristol-Myers Squibb) induce apoptosis in CML but not in healthy tissues, which is thought to result from addiction of CML cells to BCR-ABL signalling. The use of TKIs has led to remarkable improvements in disease outcome, in turn making TKIs the gold standard front line CML therapeutics. Importantly, although TKIs do induce disease remissions in most CML patients, they are not curative because of their incapacity to eradicate CML-LSC. Moreover, acquired resistance to TKIs is commonly observed and requires the prompt introduction of other TKIs that retain activity against BCR-ABL (Talpaz et al., 2002; Sawyers et al., 2002). Therefore, a timely and accurate follow-up is crucial for the management of CML and for effective therapeutic decisions (Druker et al., 2006; Kantarjian et al., 2008; O’Brien et al., 2003; Lahaye et al., 2005; Cervantes et al., 2003; Branford et al., 2003; Hughes & Branford, 2006). Additionally, such relapses are thought to result from the activation and proliferation of otherwise quiescent and therapy-resistant LSCs (Graham et al., 2002; Copland et al., 2006). Newer molecular therapies are being developed to eradicate the LSC pool by targeting critical signaling molecules that are essential for LSC maintenance.

6. CML monitoring

The remarkable progress in the treatment of CML over the past decade has been accompanied by steady improvements in our ability to accurately and sensitively monitor the status of the disease with the use of molecular markers, aimed at recognizing the depth of remission, and by use of readings to guide the choice of strategy for therapeutic interventions (Hughes et al., 2006).

However, the identification of patients that will experience a failure of TKI treatment, and appropriately altering the therapeutic strategy based on such monitoring, remains a challenge.

Routine CML diagnostics largely relies nowadays on traditional blood cell count, cytogenetic analysis (standard karyotype with or without fluorescence in situ hybridization-FISH), and real time quantitative polymerase chain reaction (RT-Q-PCR) for BCR-ABL messenger RNA (mRNA). These tests allow defining the haematological, cytogenetic, and molecular response to treatment, respectively (Kantarjian et al., 2008; Hughes et al., 2006). The haematological response to treatment is assessed by peripheral blood cell counts and by spleen size, and is classified as:

1. Complete haematological response (CHR): normalization of peripheral blood counts with no immature blood cells and with disappearance of any sign of disease

2. Partial haematological response (PHR): presence of immature blood cells and/or persistent splenomegaly. The next level of response is the cytogenetic one (CyR), defined as a decrease in the number of Ph+metaphases in a bone marrow aspirate (using ≥ 20 metaphases). This is categorized as:

   1. Complete cytogenetic response (CCyR): 0% Ph+ metaphases
   2. Partial cytogenetic response (PCyR): 1-35% Ph+ metaphases
   3. Minor cytogenetic response: 36-65% Ph+ metaphases
Towards the Cure of CML by the Molecular Approach Strategy

4. Minimal cytogenetic response: 66-95% Ph+ metaphases
CCyR or PCyR configure a major cytogenetic response (MCyR). Finally, residual leukaemia cells (minimal residual disease, MRD) can be detected using RT-Q-PCR. Particularly, the molecular response is defined as a decrease of the BCR-ABL to control gene transcript ratio according to the International Scale (IS) (see below):

1. **Complete molecular response (CMR):** undetectable level of chimeric transcript
2. **Major molecular response (MMR):** reduction in transcript levels of at least 3-log from standard baseline level (which represent 100% on the International Scale) or ≤1%.

### 6.1 Cytogenetic and FISH

The Ph chromosome can be detected by standard cytogenetic techniques in the vast majority of patients (Osarogiagbon, 1999). In patients who are cytogenetically Ph chromosome negative (Ph–), molecular techniques such as FISH and RT-Q-PCR may be useful in detecting BCR-ABL. Cytogenetic analysis is typically performed by chromosome banding of at least 20 bone marrow cells in metaphase allowing to identify the t(9:22) translocation (Haferlach et al., 2007). In addition, cytogenetic also allows to define any additional chromosomal abnormality (i.e. additional Ph chromosome, isochromosome 17q, trisomy 8, or trisomy 19), thereby providing additional prognostic information. Baccarani et al. recommend that, at diagnosis, two cytogenetic analyses are performed in order to increase the sensitivity of the method. Furthermore, if less than 20 metaphases are visualized, the cytogenetic analysis should be validated by FISH or by RT-Q-PCR (see below) (Baccarani et al., 2008). Importantly, in 5% of CML cases no cytogenetically-detectable Ph chromosome can be demonstrated, since the BCR-ABL fusion oncogene derives from a submicroscopic genetic fusion. In these cases, FISH or RT-Q-PCR will demonstrate the presence of the specific genetic abnormality. Traditional FISH uses 5’ BCR and 3’ ABL fluorescent probes of different colours while more recent FISH reagents use 3-4 probes (D-FISH). Such probes can detect the variant translocations leading to Ph chromosome formation and are also associated with low false positive rates (Dewald et al., 1998; Wang et al., 2001; Landstrom & Tefferi, 2006; Sinclair et al., 1997; Seong et al., 1995). Interphase or hypermetaphase FISH can be performed on peripheral blood specimen or bone marrow aspirates, respectively. Interphase FISH is applicable to a larger population of cells since does not require cycling cells. On the other hand, this technique is associated with a background signal greater than 1-5% (depending on the specific probe used in the assay) (Cuneo et al., 1998; Le Gouill et al., 2000; Lesser et al., 2002; Raanani et al., 2004). Hypermetaphase FISH is applicable only to dividing bone marrow cells (Schoch et al., 2002). This approach is more sensitive and can analyze up to 500 metaphases at a time. Usually, FISH results correlate with traditional cytogenetic analysis and with RT-Q-PCR results, thus remaining a convenient and sensitive diagnostic tool (see below).

### 6.2 PCR-based approaches to CML monitoring

Nested reverse transcriptase PCR can detect one CML cell in a background of ≥ 100,000 normal cells (Martinelli et al., 2006). However, it remains a purely qualitative assay which is only capable of demonstrating the presence or absence of CML cells. Nested-PCR is normally only used to confirm the achievement of CMR. RT-Q-PCR methods are less sensitive than qualitative PCR (by 0.5-1 order of magnitude) but they have the advantage of determining the actual percentage of BCR-ABL transcripts and can therefore be used to
track changes in the number of leukemic cells over time (Lowenberg, 2003; Hughes et al., 2003; Merante et al., 2005; Mauro et al., 2004; Cortes et al., 2004). Currently, RT-QPCR for BCR-ABL is the recommended approach for routine follow-up of CML patients and is considered the gold standard test for routine therapeutics decision. The BCR-ABL transcript levels are expressed as a percentage ratio of BCR-ABL compared to ABL transcripts. ABL acts as control gene to compensate for variations in the quality of the RNA and for differences in the efficiency of the reverse transcription reaction. The last years have seen numerous efforts to standardize the molecular approaches to CML monitoring as well as their interpretation criteria. In order to harmonise the results across laboratories worldwide, a standard pre-treatment baseline value for each laboratory was established. Thus, a molecular response is defined by reductions from an absolute baseline (common to all) rather than a relative baseline (individualized). This ensures that patients with the same level of response have the same degree of residual disease. Additionally, under- or over-estimation of the extent of response due to individual variations is avoided by using a common standard baseline. According to the international reporting scale (IS) the absolute BCR-ABL value to define major molecular response is standardized at 0.1% (or 3 log) reduction from the laboratory-specific pretreatment standard baseline (Hochhaus & Dreyling, 2008; Hochhaus et al., 1996). A value of 1.0% is approximately equivalent to the achievement of a CCyR and a CMR is achieved when transcripts are undetectable (Branford et al., 2006; Muller et al., 2007, 2008). Because of its high sensitivity, CML monitoring by RT-Q-PCR enables to define an early loss of response once CCyR has been achieved (Wang, 2000, Press et al., 2006). Additionally, early molecular monitoring after initiation of treatment helps to identify patients at higher risk of relapse after pharmacological treatment onset as well as after allogeneic bone marrow transplantation (Olavarria et al. 2002; Lange et al., 2004; Asnafi et al., 2006). Finally, another advantage of CML monitoring by RT-Q-PCR is the feasibility of this method on peripheral blood samples. In a large cohort of patients monitored to BCR-ABL mRNA levels after allogeneic bone marrow transplantation, we found that peripheral blood and bone marrow samples perform equally well in terms of sensitivity in relapse detection and show a very good correlation of results. Thus, molecular monitoring of CML with RT-Q-PCR can be performed using peripheral blood samples instead of bone marrow (Ballestrero et al., 2009). The drawbacks of this method include a substantial incidence of false negative tests, which on the other hand, is strongly reduced when serial evaluations are performed. Nowadays, RT-Q-PCR monitoring is included as integral part of the management of CML patient treated with TKIs and must be performed every 3 months even in patients in MMR. An increase in BCR-ABL levels of 2 to 5 fold is an early sign of relapse, and suggests the need to switch to another type of treatment as soon as possible.

6.3 Mechanisms of resistance
A growing problem in the treatment of CML is resistance to treatment since most patients in chronic phase initially respond to TKIs but subsequently relapse and/or progress to accelerated phase or blast crisis (Talpaz et al., 2002; Sawyers et al., 2002). Primary resistance, defined as the failure to achieve initial response to therapy and is only seen in approximately 5% of newly diagnosed patients in chronic phase of CML (Apperley, 2007). Acquired resistance, defined as the loss of previous response, is more common. About 10-
15% of patients in TKIs treatment develop treatment failure at a rate of approximately 1-4%/year). Resistance to TKIs may be primary or secondary and is usually classified in BCR-ABL-dependent or -independent. The BCR-ABL-dependent mechanisms include reactivation of BCR-ABL signaling through mutations in the ABL kinase domain (KD), and increased production of BCR-ABL at the genomic (gene amplification) or transcript (overexpression) levels (Campbel et al., 2002, Morel et al., 2003; Hochhaus et al., 2002). Conversely, BCR-ABL independent resistance mechanisms involve: i) a drop in the intracellular drug concentration through expression of drug efflux (such as multidrug-resistant P-glycoprotein MDR-1) (Mahon et al., 2000; le Coutre et al., 2000) or drug influx (such as hOCT1 that affects intracellular drug availability) (Thomas et al., 2004) genes; ii) activation of Src family of kinases (SFKs); and iii) acquisition of additional chromosomal abnormalities with Ph-chromosome (O’Dwyer et al., 2002, 2004; Schoch et al., 2003).

Although gene amplification occurs more frequently than point mutations (10⁻⁴ per cell division vs. 10⁻⁹ (Hochhaus A et al., 2002) clinical resistance is much more likely to be due to a point mutation in the BCR-ABL TK domain than to BCR-ABL amplification (Willis et al., 2005). To date more than 50 mutations have been identified, each of which arises at variable frequencies and with different consequences (Jabbour et al., 2006; Shah et al., 2002; Branford et al., 2002; Hofmann et al., 2002; Roche-Lestienne et al., 2002; Deninger et al., 2000; Soverini et al., 2004, 2005; Chu et al., 2005; Nicolini et al., 2006; Barth et al., 2002; Irving et al., 2004; Wei et al., 2006; Wang et al., 2006). Mutations may occur in various ATP-binding sites, such as the phosphate-binding loop (P-loop), activation site, catalytic site, or other areas in the BCR-ABL structure. Depending on the mutation site, resistance to imatinib will either be absolute or relative, or it will be clinically irrelevant. Earlier studies have associated P-loop mutations and the T315I mutation with the worst outcomes (Cortes et al., 2007). Mutations within the P-loop site are found in 30-40% of the resistant cases and reduce susceptibility to imatinib by 70 to 100 folds. The T315I mutation in BCR-ABL occurs in 0.16-0.32% of newly diagnosed patients in chronic phase, leading to substitution of threonine 315 with isoleucine. This “gatekeeper” mutation also affects the response to the currently existing second-generation TKIs. Therefore, upon its identification, patients should be considered for alternative pharmacological treatments or for allogeneic bone marrow transplantation.

6.4 Mutational analysis

A careful mutational screening allows the timely identification of potential mutant clones and suggests the most suitable second-line treatment based on the in vitro sensitivity of the specific mutation. The technologies used to identify and quantify the ABL KD mutations include: direct sequencing (Branford et al., 2003), subcloning and sequencing, denaturing-high performance liquid chromatography analysis (DHPLC), pyrosequencing and allele specific oligonucleotide PCR. Direct sequencing represents the most widespread method used for routine monitoring. Its main drawback is the low detection limit (20%) which is responsible for false negative results. Fluorescent-based allele-specific oligonucleotide PCR (ASO-PCR) assays have higher detection limit (0.1%), although their main drawback is that the search for specific mutations does not include screening of the entire KD region of the BCR-ABL gene. Nowadays, numerous groups perform DHPLC to monitor CML patients, followed by a sequence analysis to confirm the data. DHPLC has a detection limit of 1-5% (Deininger et al., 2004). Mutation studies might be performed on peripheral blood or bone
marrow although a direct comparison of these two types of samples has not been done yet. The search for BCR-ABL mutations should be performed, according to NCCN CML guidelines (NCCN Clinical Practice Guidelines in Oncology, 2010), in the following conditions:

1. Progression to accelerated or blast phase
2. Treatment failure
3. Suboptimal therapeutic responses
4. Increasing BCR-ABL levels (5 to 10 fold in mRNA)

### 6.5 Scheduling CML diagnostics and monitoring

An effective CML monitoring entails an appropriate follow up-schedule (Baccarani et al., 2006). Evidence obtained in clinical trials has prompted experts to formulate consensus recommendations to assess the response to treatment in patients with Ph+ CML (Quintas-Cardama & Cortes, 2005). In the diagnostic setting, bone marrow cytogenetics is recommended before initiation of treatment. Additionally, a nested PCR confirms the diagnosis of CML and establishes the type of BCR-ABL fusion transcript present. Bone marrow cytogenetics is able to detect chromosomal abnormalities that FISH is not able to detect. However, if bone marrow collection is not feasible, FISH on peripheral blood specimen with dual probe (BCR and ABL genes) is a suitable tool to confirm the diagnosis. Subsequently, the cytogenetic evaluation is recommended at 6 and 12 months from the beginning of treatment. If a CCyR is achieved at 6 months, it is not necessary to repeat the cytogenetic evaluation at 12 months. If patients is not in a CCyR at 12 months, a cytogenetic evaluation should be repeated at 18 months. Once cytogenetic remission is achieved, residual disease should be monitored using BCR-ABL transcript levels by RT-Q-PCR, which is the most sensitive technique to monitor BCR-ABL. The hybrid transcript levels should be measured every 3 months at the beginning of treatment and then every 3-6 months since a CCyR is achieved. A steady decline in BCR-ABL transcripts indicates an ideal response to therapy. Rising level of BCR-ABL transcript (1 log increase) following the achievement of a MMR, mandates to repeat the molecular analysis after 1 month (Baccarani et al., 2006). If the result is confirmed, bone marrow cytogenetics should be performed, BCR-ABL quantifications by RT-Q-PCR should be scheduled every month, and a kinase domain mutational analysis should also be done (Wang et al., 2003). The evaluation of the hematologic response foresees that, starting from treatment onset, blood cell counts are performed every 2 weeks until a stable CHR is achieved, then every 3 months (Deininger, 2005). If the patient fails to achieve CHR by 3 months, the treatment is generally regarded as a failure, indicating the need to consider alternative therapeutic strategies.

In summary, the international guidelines recommend the following testing schedule when monitoring treatment of CML patients:

1. Hematologic responses should be assessed at diagnosis, then every 2 weeks until a CHR has been achieved and confirmed, then every 3 months or as required.
2. Cytogenetic responses should be assessed at diagnosis, and every 6 months until a CCyR is achieved and confirmed, then every 12 to 36 months as long as MMR is stable
3. Molecular responses should be assessed every 3 months, or monthly if an increasing BCR-ABL transcript level is detected.
4. Mutational analysis in occurrences of suboptimal response or failure; recommended before changing to other TKIs or other therapies
FISH may be preferred over conventional cytogenetics as it can evaluate more cells and peripheral blood can be used instead of bone marrow. However it is only recommended prior to treatment to identify cases of Ph-, BCR-ABL CML and those with variant translocations, Ph amplification, or del9q+.

Fig. 1. Proposed algorithm for CML monitoring according to the National Comprehensive Cancer Network guidelines.

7. Conclusions

Chronic myeloid leukaemia is a biological model of how the molecular understanding of a disease is able to provide the substrate for therapy and diagnostics. The recent molecular analysis of the leukaemia cell has generated an extraordinary range of discoveries about the anomalies developed during the cell growth, promoting the development of innovative therapeutic approaches for this type of hematopoietic neoplasia. In particular with the introduction of TKIs we have embarked on a journey aiming to reduce disease burden and prolonging survival. Additionally the molecular tools to monitor disease and characterize resistance are remarkably effective not only in the diagnostic evaluation but even in the management of CML patients. While traditional cytogenetics with or without FISH and qualitative nested-PCR are essential for the diagnosis of CML, serial RT-Q-PCRs are the mainstay of therapeutic monitoring and MDR assessment (Kantarjian et al., 2008). In cases of treatment failure, highlighted by increasing BCR-ABL levels and/or by loss of hematologic and cytogenetic responses, mutational analysis to identify KD mutations should be considered in order to meet the better treatment decisions (i.e. use alternative TKIs or stem cell transplantation) (Hughes et al., 2006). Additionally, an early identification of treatment failure increases the chance that alternative treatments will be effective (Jabbour et al., 2009). However the major current impediment to cure for CML patients resides in the cancer stem cell population that is neither oncogene addicted nor sensitive to TKIs. Thus, one of the major challenges is to recognize as early as possible the patient destined to fail TKIs to revise the therapeutic strategy. Additionally, an early identification of treatment failure increases the chance that alternative treatments will be effective.

Hence the need for increasingly sophisticated technologies for an early detection of molecular relapse. In this field the comprehensive analysis of the CML genome, by the
single nucleotide polymorphism arrays, will provide the basis for a molecular approach to guide therapeutic decisions. (Boultwood et al., 2010) In summary the CML represents one of the best examples of tumour malignancies and despite the numerous advantages of modern technologies, it is important to continue interpreting laboratory data within the clinical context of the patient in order to effectively and inexpensively utilize current and nascent laboratory tools.

8. Acknowledgment
This work was supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship and by Associazione Cristina Bassi Onlus

9. References
Towards the Cure of CML by the Molecular Approach Strategy


Towards the Cure of CML by the Molecular Approach Strategy


Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N et al. (2002). Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100: 1014-1018.


This book comprises a series of chapters from experts in the field of diagnosis and treatment of myeloid leukemias from all over the world, including America, Europe, Africa and Asia. It contains both reviews on clinical aspects of acute (AML) and chronic myeloid leukemias (CML) and original publications covering specific clinical aspects of these important diseases. Covering the specifics of myeloid leukemia epidemiology, diagnosis, risk stratification and management by authors from different parts of the world, this book will be of interest to experienced hematologists as well as physicians in training and students from all around the globe.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
